← SynDRA
DEXRAZOXANE
SynDRA canonical compound SYN0020004 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · Rx/OTC |
|---|
| Primary target(s) | TOP2A | TOP2B |
|---|
| Mechanism of action | chelating agent | topoisomerase inhibitor |
|---|
| Indication | cardiomyopathy |
|---|
| Disease area | cardiology |
|---|
All known targets
Mechanisms of action (all sources)
- TOP2A INHIBITOR
- DNA topoisomerase II inhibitor
- TOP2B INHIBITOR
- chelating agent
- topoisomerase inhibitor
- Modulator
Drug classes
- Cytoprotective Agent
- Antineoplastic Agents
- Cardiotonic Agents
- Cardiovascular Agents
- Enzyme Inhibitors
- Protective Agents
- Topoisomerase II Inhibitors
- Topoisomerase Inhibitors
ATC classes
- V03A · ALL OTHER THERAPEUTIC PRODUCTS
Cross-references
Synonyms
- zinecard
- savene
- totect
- dexrazoxane hydrochloride
- dexrazoxane HCl
- Dexrazoxano
- Razoxane (+)-form
- Razoxane, (s)-
- Razoxane, d-
- ADR-529
- ICRF-187
- NSC-169780
- Cardioxane
- Zinecard
- (S)-4,4'-(Propane-1,2-diyl)bis(piperazine-2,6-dione)
- ICRF 187
- Dexrazoxanum
- Dextrorazoxane
- Dexrazoxanum [INN-Latin]
- Dexrazoxano [INN-Spanish]
- Desrazoxane
- Eucardion
- (+)-(S)-4,4'-Propylenedi-2,6-piperazinedione
- Dexrazone
- (+)-1,2-Bis(3,5-dioxo-1-piperazinyl)propane
- HSDB 7319
- UNII-048L81261F
- NSC169780
- dyzoxane
- BRN 5759131
- CHEBI:50223
- 4-[(2S)-2-(3,5-dioxopiperazin-1-yl)propyl]piperazine-2,6-dione
- NSC 169780
- AK-72797
- Razoxanum
- Savene
- TopoTect
- Totect
Reported adverse events
- Alopecia
- Fatigue
- Infection
- Nausea
- Phlebitis
- Stomatitis
- Vomiting
- Dysphagia
- Erythema
- Extravasation
- Malaise
- Neurotoxicity
Look up DEXRAZOXANE in the interactive SynDRA portal →